Could an old antibiotic tame ulcerative colitis?
NCT ID NCT06201793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the antibiotic minocycline to standard mesalamine treatment helps control mild-to-moderate ulcerative colitis. 46 adults took part. Researchers measured disease activity using a symptom score. The trial is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- minocycline (an antibiotic) added to standard mesalamine treatment
- What this could lead to
- If it works, adding minocycline could help control ulcerative colitis symptoms better than mesalamine alone.
- What could go wrong
- This is a small, early-phase trial with only 46 people. Results may not apply to everyone, and minocycline can cause side effects like dizziness or antibiotic resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
46 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine) Exclusion Criteria: Patients with severe UC Pregnancy and lactating females Significant liver and kidney function abnormalities Diabetic patients Patients with Colorectal cancer patients Patients taking rectal or systemic steroids Patients on immunosuppressants or biological therapies Patients taking antacids, anticoagulants, bactericidal antibiotics, oral contraceptives, and isotretinoin. Addiction to alcohol and / or drugs Known allergy to the studied medications History of complete or partial colectomy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Inflammatory bowel diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, Mansoura University
Al Mansurah, 7650001, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Can early symptom relief predict who stays on IBD biologic?
- Can a liquid diet calm Crohn's in kids?
- Which IBD therapy works best for kids? researchers compare two approaches
- Massive Real-World database aims to map how chronic diseases interact